Genaera Corporation (NASDAQ: GENR)
Genaera Corporation (NASDAQ: GENR) has their efforts focused on advancing the science and treatment of metabolic diseases. They have identified significant market opportunities with a first-in-class molecule that may revolutionize the treatment paradigm for obesity and type 2 diabetes. They currently have two products in their pipeline: MSI-1436 , the core internal asset of Genaera designed to treat obesity and has applicability in type 2 diabetes; and MEDI-528, which is under evaluation in Phase 2 clinical studies for the treatment of asthma. For further information, visit the Company's web site at www.genaera.com Generex is focused on researching, developing, and commercializing…